نسخه فارسی
نسخه فارسی

D.SAP, an Apple-Based Formulation Can Treat SARS-CoV-2

D.SAP, an Apple-Based Formulation Can Treat SARS-CoV-2

Introduction: The SARS-CoV-2 virus is a virus that may cause severe respiratory disorders with an unclear rate of death. Natural vinegar may have an immune-boosting quality that eectively ghts inuenza-like respiratory infections. We aimed  to evaluate the role of a specially formulated Iranian  apple vinegar called Dezhakam sap  (D.SAP) in the mice model of covid-19 in the treatment of infection and reduction of covid19-associated lung inammation. Methods: We designed covid-19-positive Inbred BALB/c mice by viral exposure. Then all mice were examined for active SARS-CoV-2 infection. Mice with positive covid-19 infection were separated into dierent groups to study the eect of treatment by dierent concentrations of D.SAP smoke for seven days. Expression assessments for viral RNA on covid-19 aected mice models for three SARS-CoV-2 genes (RDRP, N, and E) and three inammation markers (IL6, IL1b, and TNF) in lung tissue of all mice were assessed using Real-time PCR. Results: Results showed a signicant decrease in viral load in the RDRP gene, N gene, and E gene in all infected rats who were treated with D.SAP compared with  o-treatment mice.  In addition, all three inammation  factor genes in infected mice that were treated with D.SAP were signicantly reduced compared to the o-treatment infected mice. Conclusion: Findings showed the eectiveness of specially formulated apple vinegar D.SAP to attack new coronavirus. Also, results may  suggest the eectiveness of D.SAP to  reduce the lethal  inammation  in  COVID-19  infection with low side eects. Anti-inammatory agents block certain substances in the body that cause inammation. D.SAP may consider a  potential  natural anti-inammatory that  may  increase the  survival rate of COVID-19  infection. It seems these eects could be related to the antimicrobial and antioxidant eects of D.SAP due to its polyphenolic compounds

Source

Your Comments





0 Comments

No comments have been posted yet.